Screener
Xeris Biopharma Holdings, Inc. XERS Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
| Assets | June 30, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Accrued trade discounts and rebates | 46,858 | 43,253 |
| Accrued returns reserve | 18,598 | 18,969 |
| Other current liabilities | 4,976 | 4,889 |
| Total current liabilities | 189,568 | 109,574 |
| Long-term debt, net of unamortized debt issuance costs | 188,807 | 220,335 |
| Non-current operating lease liabilities | 30,542 | 31,531 |
| Other liabilities | 12,722 | 8,398 |
| Total liabilities | 421,639 | 369,838 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Xeris Biopharma Holdings, Inc.'s total current liabilities?
- Xeris Biopharma Holdings, Inc. (XERS) reported total current liabilities of $189.57M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s total current liabilities changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s total current liabilities increased by 99.2% year-over-year, from $95.17M to $189.57M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s total current liabilities has grown at a 31.2% compound annual growth rate (CAGR), from $28.21M to $109.57M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Xeris Biopharma Holdings, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude